Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Neuro-Oncology|February 24, 2024
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant gliomaYazmin Odia, Carl Koschmann, Nicholas A Vitanza, et al.
Neuro-Oncology Advances|July 10, 2020
Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabineAdam L Green, Patrick Flannery, Todd C Hankinson, et al.
Cancers|July 12, 2025
Prognostic Features of Recurrent Midline and H3 K27M-Mutant GliomaStephen J Bagley, Yoshie Umemura, Joe S Mendez, et al.
Science Translational Medicine|March 4, 2016
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in gliomaCarl Koschmann, Anda-Alexandra Calinescu, Felipe J Nunez, et al.
Npj Biomedical Innovations|April 24, 2026
Automated microinjection for zebrafish xenograft modelsYi Ding, Kees-Jan van der Kolk, Wietske van der Ent, et al.
Neuro-Oncology|February 4, 2026
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine gliomaAndrea Timpanaro, Edward Z Song, Ryma Toumi, et al.
Cancer Cell|August 16, 2020
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine GliomasChan Chung, Stefan R Sweha, Drew Pratt, et al.
Biorxiv : the Preprint Server for Biology|September 15, 2025
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine gliomaAndrea Timpanaro, Edward Z Song, Ryma Toumi, et al.
Neuro-Oncology|July 21, 2026
Early increase in apparent diffusion coefficient predicts favorable response to Dordaviprone (ONC201) therapy in H3K27M-mutant diffuse midline gliomaBenison C Lau, Diala P Ajaero, Benjamin A Hoff, et al.
Cell Reports|January 12, 2022
ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitizationTingting Qin, Brendan Mullan, Ramya Ravindran, et al.
Pageof 11